Search results
Results from the WOW.Com Content Network
Since lupus nephritis is a serious, disabling, and possibly life-threatening illness, it is not surprising to see mortality in lupus nephritis clinical trials. Voclosporin safety information originates from a total of 267 patients who received 23.7 mg BID and an additional 88 patients who received 39.5 mg BID.
Ianalumab (INN; [1] development code VAY736) is a monoclonal antibody that is being investigated for autoimmune hepatitis, multiple sclerosis, pemphigus vulgaris, rheumatoid arthritis, Sjogren's disease, and systemic lupus erythematosus. [2] [3] [4] This drug is being developed by Novartis. In 2021 ianalumab was undergoing Phase II/III trials.
The proliferative forms of lupus nephritis are associated with a higher risk of progression to end stage kidney disease. [21] Black and Hispanic people with lupus nephritis are more likely to present with severe disease at initial presentation (with more proteinuria and more extensive histopathologic changes) and progress to end stage kidney ...
On Tuesday, UCB SA (OTC:UCBJY) (OTC:UCBJF) and Biogen Inc. (NASDAQ:BIIB) presented detailed results from the Phase 3 PHOENYCS GO study evaluating dapirolizumab pegol (DZP) for systemic lupus ...
Idera Announces Initiation of Lupus Clinical Development Program with Phase 1 Trial of IMO-8400 Presents IMO-8400 Preclinical Data Supporting Autoimmune Activity at ACR/AHRP 2012 CAMBRIDGE, Mass ...
Biogen and Belgian partner UCB said on Tuesday their experimental lupus treatment met the main goal of a late-stage trial in patients with the chronic disease, a surprise result after the drug ...
Belimumab was not effective in Phase II clinical trials for rheumatoid arthritis. [30] It was moderately effective in Phase II trials for Sjögren syndrome. [31] In December 2020, belimumab was approved by the FDA as a treatment for lupus nephritis in combination with standard treatment. [32]
1 per million people [46] IgA nephropathy: Kidneys: IgA autoantibodies Confirmed 3.5 per 100,000 [47] Membranous nephropathy: Kidneys: Anti-PLA2R antibodies Confirmed 10 per 100,000 [48] Lupus nephritis: Kidneys: Anti-dsDNA, Anti-Sm, Anti-nuclear antibodies Confirmed Up to 60% of those with Lupus [49] Interstitial nephritis: Kidneys: Various ...